BIOMAT Database Logo BIOMAT Database Logo

Changes in NT-proBNP in young children with congenital heart malformations. 2014

Angela Butnariu, and Mihaela Iancu, and Gabriel Samaşca, and Manuel Chira, and Iulia Lupan

OBJECTIVE We measured serum NT-proBNP levels in 2 groups of young patients (0-36 months) with congestive heart failure (CHF) secondary to congenital heart malformations (CHM). METHODS The first group included 23 patients prior to surgery for heart malformations. The second group included 12 patients with CHM within 24 hours post-operation. NT-proBNP levels were measured by an enzyme-linked immunosorbent immunoassay (ELISA) using the Chem Well 2910 (Awareness Technology Inc.) automated analyzer. RESULTS NT-proBNP values were 4 times higher in patients with unoperated CHM compared to healthy controls (P < 0.001), and 12 times higher in patients with CHM 24 hours after surgery compared to controls (P = 0.0001). CONCLUSIONS These results demonstrated significant changes in NT-proBNP concentrations before and after surgery to correct congenital heart malformations.

UI MeSH Term Description Entries
D007223 Infant A child between 1 and 23 months of age. Infants
D008297 Male Males
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D002675 Child, Preschool A child between the ages of 2 and 5. Children, Preschool,Preschool Child,Preschool Children
D005260 Female Females
D006330 Heart Defects, Congenital Developmental abnormalities involving structures of the heart. These defects are present at birth but may be discovered later in life. Congenital Heart Disease,Heart Abnormalities,Abnormality, Heart,Congenital Heart Defect,Congenital Heart Defects,Defects, Congenital Heart,Heart Defect, Congenital,Heart, Malformation Of,Congenital Heart Diseases,Defect, Congenital Heart,Disease, Congenital Heart,Heart Abnormality,Heart Disease, Congenital,Malformation Of Heart,Malformation Of Hearts
D006333 Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. Cardiac Failure,Heart Decompensation,Congestive Heart Failure,Heart Failure, Congestive,Heart Failure, Left-Sided,Heart Failure, Right-Sided,Left-Sided Heart Failure,Myocardial Failure,Right-Sided Heart Failure,Decompensation, Heart,Heart Failure, Left Sided,Heart Failure, Right Sided,Left Sided Heart Failure,Right Sided Heart Failure
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000367 Age Factors Age as a constituent element or influence contributing to the production of a result. It may be applicable to the cause or the effect of a circumstance. It is used with human or animal concepts but should be differentiated from AGING, a physiological process, and TIME FACTORS which refers only to the passage of time. Age Reporting,Age Factor,Factor, Age,Factors, Age
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune

Related Publications

Angela Butnariu, and Mihaela Iancu, and Gabriel Samaşca, and Manuel Chira, and Iulia Lupan
Urinary values of NT-proBNP in children with congenital heart disease - Is it feasible?
October 2020, Clinica chimica acta; international journal of clinical chemistry,
Angela Butnariu, and Mihaela Iancu, and Gabriel Samaşca, and Manuel Chira, and Iulia Lupan
Perioperative NT-proBNP level: Potential prognostic markers in children undergoing congenital heart disease surgery.
August 2017, The Journal of thoracic and cardiovascular surgery,
Angela Butnariu, and Mihaela Iancu, and Gabriel Samaşca, and Manuel Chira, and Iulia Lupan
Serum NT-proBNP Levels Are Not Related to Vitamin D Status in Young Patients with Congenital Heart Defects.
January 2016, Disease markers,
Angela Butnariu, and Mihaela Iancu, and Gabriel Samaşca, and Manuel Chira, and Iulia Lupan
Longitudinal NT-proBNP: Associations With Echocardiographic Changes and Outcomes in Heart Failure.
May 2024, Journal of the American Heart Association,
Angela Butnariu, and Mihaela Iancu, and Gabriel Samaşca, and Manuel Chira, and Iulia Lupan
Diagnostic performance of BNP and NT-ProBNP measurements in children with heart failure based on congenital heart defects and cardiomyopathies.
November 2010, Clinical biochemistry,
Angela Butnariu, and Mihaela Iancu, and Gabriel Samaşca, and Manuel Chira, and Iulia Lupan
[Congenital malformations in young children].
March 1977, Fel'dsher i akusherka,
Angela Butnariu, and Mihaela Iancu, and Gabriel Samaşca, and Manuel Chira, and Iulia Lupan
Perioperative urinary NT-ProBNP values and their usefulness as diagnostic and prognostic markers in children with congenital heart disease.
July 2021, Clinica chimica acta; international journal of clinical chemistry,
Angela Butnariu, and Mihaela Iancu, and Gabriel Samaşca, and Manuel Chira, and Iulia Lupan
[Changes in NT-proBNP levels in patients with atrial fibrillation related to heart failure].
August 2010, Vnitrni lekarstvi,
Angela Butnariu, and Mihaela Iancu, and Gabriel Samaşca, and Manuel Chira, and Iulia Lupan
Asymmetrical dimethylarginine--more sensitive than NT-proBNP to diagnose heart failure in adults with congenital heart disease.
January 2012, PloS one,
Angela Butnariu, and Mihaela Iancu, and Gabriel Samaşca, and Manuel Chira, and Iulia Lupan
Diagnostic value of analysis of H-FABP, NT-proBNP, and cTnI in heart function in children with congenital heart disease and pneumonia.
January 2014, European review for medical and pharmacological sciences,
Copied contents to your clipboard!